• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟喹诺酮类药物对骨科患者产超广谱β-内酰胺酶(ESBL)阳性和ESBL阴性分离株的突变预防浓度比较

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Isolates from Orthopedic Patients.

作者信息

Zou Peng, Chen Zhiquan, Tu Jijun, Chen Xinfeng, Liu Xuejian

机构信息

The Department of Orthopedics, Zhengzhou Seventh People's Hospital, Zhengzhou, China.

出版信息

Microb Drug Resist. 2024 Sep;30(9):391-397. doi: 10.1089/mdr.2024.0023. Epub 2024 Jul 17.

DOI:10.1089/mdr.2024.0023
PMID:39019029
Abstract

The majority of isolates possess the extended-spectrum beta-lactamase (ESBL) enzymes. Therefore, can easily develop drug resistance. How to effectively overcome the problem of drug resistance in is still a research hotspot. This study aimed to compare the mutant prevention concentration (MPC) of ESBL-positive and ESBL-negative isolated from orthopedic patients, which may provide a basis for the effective use of drugs to control the enrichment of resistance mutants of . The MPC values of 55 isolates of ESBL-positive against 4 fluoroquinolones were 32 µg/mL for levofloxacin and gatifloxacin, 16 µg/mL for ciprofloxacin, and 4 µg/mL for gemifloxacin. The selection index value was 8 for levofloxacin and ciprofloxacin and 2 for gemifloxacin and gatifloxacin, respectively. For ESBL-negative isolates, the MPC values were 16 µg/mL for levofloxacin and ciprofloxacin, 4 µg/mL for gemifloxacin, and 32 µg/mL for gatifloxacin. The selection index value was 8 for levofloxacin and ciprofloxacin, 2 for gemifloxacin, and 4 for gatifloxacin. For the ESBL-positive , the %T>MIC order was gemifloxacin > levofloxacin > ciprofloxacin > gatifloxacin. For the ESBL-negative the %T>MIC order was levofloxacin > gemifloxacin > ciprofloxacin > gatifloxacin. The mutant-preventing ability of gatifloxacin and gemifloxacin was the strongest among the 4 fluoroquinolones. So gemifloxacin may be the first choice of drug to treat infection.

摘要

大多数分离株都具有超广谱β-内酰胺酶(ESBL)。因此,其很容易产生耐药性。如何有效克服其耐药性问题仍是一个研究热点。本研究旨在比较从骨科患者中分离出的ESBL阳性和ESBL阴性菌株的突变预防浓度(MPC),这可能为有效使用药物控制菌株耐药突变体的富集提供依据。55株ESBL阳性菌株对4种氟喹诺酮类药物的MPC值,左氧氟沙星和加替沙星为32μg/mL,环丙沙星为16μg/mL,吉米沙星为4μg/mL。左氧氟沙星和环丙沙星的选择指数值分别为8,吉米沙星和加替沙星的选择指数值分别为2。对于ESBL阴性菌株,左氧氟沙星和环丙沙星的MPC值为16μg/mL,吉米沙星为4μg/mL,加替沙星为32μg/mL。左氧氟沙星和环丙沙星的选择指数值为8,吉米沙星为2,加替沙星为4。对于ESBL阳性菌株,%T>MIC顺序为吉米沙星>左氧氟沙星>环丙沙星>加替沙星。对于ESBL阴性菌株,%T>MIC顺序为左氧氟沙星>吉米沙星>环丙沙星>加替沙星。加替沙星和吉米沙星在4种氟喹诺酮类药物中的突变预防能力最强。所以吉米沙星可能是治疗菌株感染的首选药物。

相似文献

1
Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Isolates from Orthopedic Patients.氟喹诺酮类药物对骨科患者产超广谱β-内酰胺酶(ESBL)阳性和ESBL阴性分离株的突变预防浓度比较
Microb Drug Resist. 2024 Sep;30(9):391-397. doi: 10.1089/mdr.2024.0023. Epub 2024 Jul 17.
2
Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.台湾产超广谱β-内酰胺酶且耐氟喹诺酮的肺炎克雷伯菌分离株的分子流行病学
J Clin Microbiol. 2002 Dec;40(12):4666-9. doi: 10.1128/JCM.40.12.4666-4669.2002.
3
In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.在药效学模型中,针对金黄色葡萄球菌的氟喹诺酮类药物突变预防浓度靶向浓度的体外活性。
Int J Antimicrob Agents. 2004 Aug;24(2):150-60. doi: 10.1016/j.ijantimicag.2004.03.011.
4
Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.
J Infect Dev Ctries. 2014 Feb 13;8(2):154-9. doi: 10.3855/jidc.3164.
5
Prevalence of two multidrug-resistant Klebsiella species in an Indian teaching hospital and adjoining community.印度一家教学医院及其周边社区中两种多重耐药克雷伯菌属细菌的流行情况。
J Infect Public Health. 2014 Nov-Dec;7(6):496-507. doi: 10.1016/j.jiph.2014.05.002. Epub 2014 Jul 2.
6
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.克林沙星、加替沙星、吉米沙星和曲伐沙星对近期耐左氧氟沙星肺炎链球菌临床分离株的活性。
Antimicrob Agents Chemother. 2000 Nov;44(11):2962-8. doi: 10.1128/AAC.44.11.2962-2968.2000.
7
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.野生型、外排阳性或含有ParC或GyrA突变的肺炎链球菌分离株的单步氟喹诺酮耐药突变体的突变预防浓度。
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
8
Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.氟喹诺酮类药物对耐环丙沙星肺炎链球菌的药效学活性
J Antimicrob Chemother. 2002 May;49(5):807-12. doi: 10.1093/jac/dkf022.
9
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.碳青霉烯类和氟喹诺酮类药物对产超广谱β-内酰胺酶细菌的药效学建模。
Clin Ther. 2004 Nov;26(11):1800-7. doi: 10.1016/j.clinthera.2004.11.009.
10
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.肺炎链球菌中吉米沙星与曲伐沙星、环丙沙星、加替沙星和莫西沙星的单步及多步耐药性选择研究
J Antimicrob Chemother. 2001 Sep;48(3):365-74. doi: 10.1093/jac/48.3.365.